Pharmaceuticals for Women’s Health Market 2018 Global Market Key Players – AbbVie, Inc.; Bayer AG and Pfizer Inc
Global Pharmaceuticals for Women’s Health Market
Description:-
Wiseguyreports.Com Adds “Global Pharmaceuticals for Women’s Health Market 2018: Global Analysis, Industry Size, Share, Trends, Application Analysis and Growth Opportunities Forecast to 2023” Wiseguyreports.Com Adds To Its Research Database
Women’s health therapeutics have a strong presence in the global pharmaceutical market, and that presence is expected to increase from approximately $x.x billion in 2017 to nearly $x.x billion by 2023, at a CAGR of x.x%. North America dominates the global women’s health market, with a marketshare of x.x% in 2017. North America will continue with its leading position, followed by Europe and Asia-Pacific, during the forecast period.
The postmenopausal osteoporosis segment leads the global women’s health therapeutics and technologies market and will continue to significantly drive market growth, followed by pregnancy disorders and management, menopause-related conditions, endometriosis and polycystic ovary syndrome.
Pharmaceutical companies in the women’s healthcare space are expanding their R&D base and doubling efforts to expand beyond reproductive health into key women’s health areas, such as menopause-related conditions and osteoporosis. Existing therapies for these health problems have issues pertaining to safety and efficacy; for instance, hormone therapy comes with serious safety concerns. Therefore, there is growing unmet need for better and safer products, particularly from growing elderly populations. Osteoporosis, similar to hormone therapy, sees increasing demand due to a growing older demographic, but safety concerns have curbed efforts to address that demand. The bisphosphonate category, while regarded by physicians as safe and effective, has suffered considerably over concerns of atypical fractures and osteonecrosis of the jaw.
Request a sample copy @ http://www.wiseguyreports.com/sample-request/3272379-pharmaceuticals-for-women-s-health-global-markets-to-2023
Women’s health therapeutics have established a very strong presence in the global pharmaceutical market over the last few decades. The market is expected to grow moderately, mainly due to patent expirations of blockbuster drugs such as Evista, the Premarin family, Forteo, Mirena, Boniva, Actonel, Gonal-F and several others. However, the launch of new drugs in the market, and novel drugs under research and development in the late-stage pipeline, has the strong potential to drive the market during the forecast period.
The global women’s health therapeutics market is dominated by Eli Lilly; Amgen, Inc.; Merck & Co, Inc.; AbbVie, Inc.; Bayer AG and Pfizer Inc. They held a significant share of the global women’s health market in 2017. Tier 1 companies dominate the market share owing to increased preference of their product portfolio, revenue from their women’s health portfolios, overall sales and the company’s global presence.
Browse full Report @ https://www.wiseguyreports.com/reports/3272379-pharmaceuticals-for-women-s-health-global-markets-to-2023
Table of Content
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst’s Credentials
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Technologies and Global Markets Overview
Disease Overview and Definitions
Market Driving Factors and Opportunities
Aging Female Population
Government Involvement and Increased Funding
Increasing Awareness Regarding Women’s Disorders and Treatments
Market Restraints
Poor Diagnosis
Availability of Alternate Treatment Options and Lifestyle Changes
Unavailability of Novel Treatments
High Cost of Treatment
Chapter 4 Pipeline Assessment and Analysis
List of Drugs in Pipeline
Overview of Osteoporosis Drug Development Pipeline
Late-stage Pipeline Drugs
Elagolix (AbbVie Inc.)
Vilaprisan (Bayer AG)
Evenity (Amgen Inc.)
Relugolix (Myovant Sciences)
Proellex (Repros Therapeutics)
Esmya (Allergan Inc.)
TX-004HR (TherapeuticsMD, Inc.)
TX-001HR (TherapeuticsMD, Inc )
………………………
Chapter 8 Competitive Landscape and Key Developments
Market Players and Strategy
Patent Analysis
List of Key Patents
Key Developments
Mergers and Acquisitions
Development of Innovative Products/Novel Product Launch
Agreements, Collaborations & Partnerships
Key Products
Chapter 9 Company Profiles
ABBVIE INC.
Company Overview
Product Information
Development and Strategies
Financials
ALLERGAN PLC.
Company Overview
Product Information
Development and Strategies
Financials
AMGEN INC.
Company Overview
Product Information
Development and Strategies
Financials
BAYER AG
Company Overview
Product Information
Development and Strategies
Financials
DAIICHI SANKYO COMPANY. LTD.
Company Overview
Product Information
Development and Strategies
Financials
ELI LILLY AND COMPANY
Company Overview
Product Information
Development and Strategies
Financials
JOHNSON & JOHNSON INC.
Company Overview
Product Information
Financials
MERCK & CO. INC.
Company Overview
Product Information
Development and Strategies
Financials
MERCK KGAA
Company Overview
Product Information
NOVO NORDISK
Company Overview
Product Information
Financials
PFIZER INC.
Company Overview
Product Information
Development and Strategies
Financials
Chapter 10 Appendix
Abbreviations Used in the Report List of Tables
Continued……….
About Us:
Wise Guy Reports Is Part Of The Wise Guy Consultants Pvt. Ltd. And Offers Premium Progressive Statistical Surveying, Market Research Reports, Analysis & Forecast Data For Industries And Governments Around The Globe. Wise Guy Reports Features An Exhaustive List Of Market Research Reports From Hundreds Of Publishers Worldwide. We Boast A Database Spanning Virtually Every Market Category And An Even More Comprehensive Collection Of Market Research Reports Under These Categories And Sub-Categories.
Contact Us:
Wise Guy Research Consultants Pvt Ltd
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Maharashtra, Pune – 411028
Posted by
Vivian Dsena
on Tuesday September 04 2018, 9:31 AM EDT.
All trademarks acknowledged.
Filed under Uncategorized.
Comments and Trackbacks closed.
Follow responses:
RSS 2.0
